TABLE 1

Noncompartmental analysis of serum harmaline PK in wild-type and Tg-CYP2D6 mice coadministered with harmaline and 5-MeO-DMT

Harmaline and 5-MeO-DMT were administered i.p. at 0 and 15 minutes, respectively.

Mice	Parameters	5-MeO-DMT 2 mg/kg			5-MeO-DMT 10 mg/kg
Mice	Parameters	Harmaline 2 mg/kg	Harmaline 5 mg/kg	Harmaline 15 mg/kg	Harmaline 5 mg/kg	Harmaline 15 mg/kg
Wild-type	C_max (µM)	0.450 ± 0.113	2.61 ± 0.48*	11.0 ± 1.5*^†	3.18 ± 0.22	10.9 ± 0.6^†
Wild-type	AUC (µM⋅min)^{^a}	27.9 ± 7.1	198 ± 10*	935 ± 166*^†	197 ± 16	269 ± 7^†
Tg-CYP2D6	C_max (µM)	0.406 ± 0.096	1.91 ± 0.14*^#	10.1 ± 0.8*^†	2.46 ± 0.51	10.0 ± 1.2^†
Tg-CYP2D6	AUC (µΜ⋅min)^{^a}	17.1 ± 3.6^#	109 ± 13*^#	416 ± 66*^#^†	111 ± 7^#	234 ± 22^#^†

↵^a AUC_{15 min→∞} for the treatments of harmaline plus 2 mg/kg 5-MeO-DMT, AUC_15→105min for the treatments of 5 mg/kg harmaline plus 10 mg/kg 5-MeO-DMT, and AUC_15→45min for the treatments of15 mg/kg harmaline plus 10 mg/kg 5-MeO-DMT.
↵^# P < 0.05 compared with wild-type mice under the same treatment; *P < 0.05 compared with the same genotype mice treated with the same dose of 5-MeO-DMT plus 2 mg/kg harmaline; ^†P < 0.05 compared with the same genotype mice treated with the same dose of 5-MeO-DMT plus 5 mg/kg harmaline.